Corcept Therapeutics Incorporated (LON:0I3Q)

Corcept Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	141.82	106.14	101.42	112.51	106.01	94.18
Depreciation & Amortization	1.15	2.36	3.45	3.48	2.24	2.17
Stock-Based Compensation	57.62	48.94	42.44	42.93	33.54	29.31
Other Operating Activities	-49.13	-38.62	-32.52	9.44	15.54	15.14
Change in Accounts Receivable	-25.09	-10.07	-3.43	-1.43	-6.27	-2.34
Change in Inventory	0.71	1.27	1.2	3.44	-3.51	-1.04
Change in Accounts Payable	2.61	5.78	4.76	-3.6	3.16	-0.74
Change in Income Taxes	2.38	1.21	8.69	0.01	0.01	0.15
Change in Other Net Operating Assets	15.4	10.03	-5.67	1.1	1.25	-0.72
Operating Cash Flow	144.65	127.04	120.32	167.89	151.97	136.12
Operating Cash Flow Growth	-6.40%	5.58%	-28.33%	10.48%	11.65%	17.68%
Capital Expenditures	-2.05	-0.14	-0.41	-0.47	-1.24	-1.09
Investment in Securities	-94.1	91.05	-113.91	136.6	-118.03	-116.74
Investing Cash Flow	-96.15	90.91	-114.33	136.13	-119.26	-117.83
Issuance of Common Stock	8.96	5.81	4.38	16.23	23.23	8.42
Repurchase of Common Stock	-31.98	-154.53	-21.67	-318.82	-11.01	-37.06
Financing Cash Flow	-23.02	-148.72	-17.28	-302.59	12.21	-28.65
Net Cash Flow	25.49	69.22	-11.29	1.43	44.92	-10.36
Free Cash Flow	142.6	126.9	119.91	167.42	150.73	135.03
Free Cash Flow Growth	-7.62%	5.83%	-28.38%	11.07%	11.63%	17.04%
Free Cash Flow Margin	22.69%	26.31%	29.84%	45.75%	42.59%	44.06%
Free Cash Flow Per Share	1.28	1.14	1.03	1.33	1.21	1.10
Cash Income Tax Paid	47.6	47.6	39.75	9.1	10.86	6.74
Levered Free Cash Flow	140.11	128.39	115.55	120.18	116.42	100.52
Unlevered Free Cash Flow	140.11	128.39	115.55	120.18	116.42	100.52
Change in Net Working Capital	6.2	-10.17	0.32	3.55	-1.75	-0.37

Source: S&P Capital IQ. Standard template. Financial Sources.